spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Soft Tissue Sarcoma 

 HSMN NewsFeed - 12 Jul 2023
Southwest Florida Proton selects RayStation
Devices Oncology
 HSMN NewsFeed - 24 Feb 2022
PANTHERx(R) Rare Selected by Aadi Bioscience to Distribute FYARRO(TM) (sirolimus protein-bound particles for injectable suspension) (albumin-bound) for Advanced Malignant Perivascular Epithelioid Cell Neoplasm (PEComa)
Biopharmaceuticals Oncology Distribution
 HSMN NewsFeed - 23 Apr 2021
GLOBAL Sarcoma Therapy Now Approved for Australian Patients
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 15 Oct 2019
Cyteir Therapeutics Secures Additional $40.2 Million in Its Series B Financing and Doses First Patient in Phase 1/2 Study of First-in-Class RAD51 Inhibitor
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 18 Jan 2019
Lilly Reports Results of Phase 3 Soft Tissue Sarcoma Study of LARTRUVO(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Jul 2018
PharmaMar Reaches an Agreement With Impilo Pharma, a Part of Immedica Group, for the Promotion and Distribution of Yondelis(R) in the Nordic Countries and Eastern Europe
Biopharmaceuticals Oncology Distribution
 HSMN NewsFeed - 22 Jun 2018
PharmaEngine Announces Positive Topline Results from Global Pivotal Trial of PEP503 (NBTXR3) in Soft Tissue Sarcoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 May 2018
CytRx Corporation Names Eric L. Curtis as Its President and Chief Operating Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 19 Apr 2017
CytRx Announces FDA Agreement on Regulatory Pathway to Approval for Aldoxorubicin in Soft Tissue Sarcomas
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 19 Dec 2016
CytRx Appoints Chief Medical Officer Dr. Daniel Levitt as Chief Operating Officer
Biopharmaceuticals Drug Delivery Oncology Personnel
 HSMN NewsFeed - 2 Dec 2016
Leading Sarcoma Expert Dr. Earl W. Brien Joins CytRx Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 Sep 2016
CHMP Recommends Approval of Lilly's Olaratumab, in Combination with Doxorubicin, for Advanced Soft Tissue Sarcoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 5 Sep 2016
Eisai Bewildered as German Institute for Quality and Efficiency in Health Care (IQWIG) Fails to Recognise Additional Benefit of Halaven(R) (eribulin) in the Treatment of Advanced Liposarcoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 29 Jan 2016
FDA Approves Eisai's Halaven(R) (eribulin mesylate) Injection for the Treatment of Patients with Advanced Liposarcoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Jan 2016
CytRx Corporation Appoints Olivia Ware as Chief Commercial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 7 Dec 2015
Merck KGaA, Darmstadt, Germany, Decides Not to Pursue Evofosfamide Further in Soft Tissue Sarcoma and Pancreatic Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 May 2015
Merck KGaA, Darmstadt, Germany, Receives FDA Fast Track Designation for Evofosfamide for the Treatment of Patients Living With Advanced Pancreatic Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Feb 2015
Topline Results of Phase 3 Trial Show Eribulin Mesylate Injection Meets Primary Endpoint of Overall Survival in Advanced Soft Tissue Sarcoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Feb 2015
U.S. FDA Grants Priority Review for YONDELIS(R) (trabectedin) for the Treatment of Patients with Advanced Soft Tissue Sarcoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Jan 2015
CytRx Announces FDA's Removal of Partial Clinical Hold for Aldoxorubicin Clinical Trials Permitting Immediate Enrollment of New Patients
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Jan 2015
CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results in Glioblastoma Multiforme (Brain Cancer)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Dec 2014
CytRx Receives Written FDA Communication Regarding Partial Clinical Hold for Aldoxorubicin Clinical Trials
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Jun 2014
EntreMed Stockholders Approve Name Change To CASI Pharmaceuticals
Biopharmaceuticals
 HSMN NewsFeed - 16 Jan 2014
CytRx Appoints Shanta Chawla, M.D. as Vice President, Clinical Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 22 Nov 2013
Threshold Pharmaceuticals Announces New Clinical Data on TH-302 and Avastin(R) (Bevacizumab) in Recurrent Glioblastoma Following Bevacizumab Failure
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Jul 2013
Oncos Therapeutics Granted Orphan Drug Designation for CGTG-102 in Soft Tissue Sarcoma (STS) by FDA and EMA
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 Mar 2013
ZIOPHARM Terminates Development of Palifosfamide in Metastatic Soft Tissue Sarcoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Nov 2012
Novel Cancer Immune Therapy Developer Oncos Therapeutics Appoints Experienced Industry Leader Frans Wuite as President and CEO
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 25 Apr 2012
Threshold Pharmaceuticals Appoints Robert Simon as Senior Vice President of Regulatory Affairs
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 17 Feb 2012
Threshold Pharmaceuticals Appoints Dr. Tillman Pearce as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Feb 2012
Threshold Pharmaceuticals and Merck KGaA Announce Global Agreement to Co-Develop and Commercialize Phase 3 Hypoxia-Targeted Drug TH-302
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Nov 2011
Threshold Pharmaceuticals Appoints Nipun Davar as Vice President of Pharmaceutical Development and Manufacturing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Nov 2011
BSD Medical Announces Broadening of NCCN Guidelines for the Treatment of Soft Tissue Sarcoma by Hyperthermia Combined with Chemotherapy
Devices Oncology
 HSMN NewsFeed - 6 Sep 2011
ZIOPHARM Oncology Appoints Caesar J. Belbel as Executive Vice President, Chief Legal Officer and Secretary
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 15 Jul 2011
ZIOPHARM Oncology Appoints Hagop Youssoufian, M.Sc., M.D., as Executive Vice President and Chief Medical Officer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Jun 2011
Spectrum Pharmaceuticals Announces Promotions of Steven M. Fruchtman, MD, to Chief Medical Officer, Head of Medical & Regulatory Affairs, and Nozar Azarnia, PhD, to Head of Biostatistics and Data Management
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jun 2011
BSD Medical Announces Clinical Role of Hyperthermia Was the Focus at European Society for Hyperthermic Oncology Meeting
Devices Oncology
 HSMN NewsFeed - 19 May 2011
Lilly Presents Data on Cixutumumab in Five Subtypes of Sarcoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Mar 2011
First Varian High Dose Rate Brachytherapy Afterloader Supplied to Leading China Cancer Hospital
Devices Oncology
 HSMN NewsFeed - 24 Feb 2011
BSD Medical Announces the Inclusion of Hyperthermia and Chemotherapy as a Recommended Cancer Treatment for High Risk Sarcoma in the NCCN Practice Guidelines
Devices Oncology
 HSMN NewsFeed - 24 Feb 2011
Spectrum Pharmaceuticals Appoints Steven M. Fruchtman, MD, an Industry Veteran, as Vice President of Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Jan 2011
ZIOPHARM Oncology Appoints Mark Thornton, M.D., Ph.D., as Executive Vice President and Chief Development Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 13 Dec 2010
Lilly Suspends Phase III Trial in Metastatic Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Nov 2010
ZIOPHARM Oncology Appoints Brian L. Hamilton, M.D., Ph.D., as Senior Vice President, Clinical Operations
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Oct 2010
ZIOPHARM Oncology Appoints Michael G. King, Jr. as Senior Vice President of Corporate Development & Communication
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 17 Jun 2010
BSD Medical Reports Hyperthermia Use with Particle Therapy Highlighted at German Society of Radiation Oncology Meeting
Devices Oncology
 HSMN NewsFeed - 6 Apr 2010
ZIOPHARM Elects George B. Abercrombie, former CEO of Hoffmann-La Roche, to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 17 Mar 2010
Radiation Breakthrough Gives Breast Cancer Patients Hope in Single Dose
Devices Oncology
 HSMN NewsFeed - 18 Feb 2010
BSD Medical Announces First Swiss Installation of the BSD-2000/3D Hyperthermia System at Kantonsspital Aarau
Devices Oncology
 HSMN NewsFeed - 18 Nov 2009
Radiation Breakthrough Gives Breast Cancer Patients Hope in Single Dose
Devices Oncology
 HSMN NewsFeed - 8 May 2009
Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Mar 2009
Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Nov 2008
BSD Medical: NCCN Clinical Practice Guidelines Indicate Significantly Superior Treatment Response When Regional Hyperthermia is Added to Chemotherapy
Devices Oncology
 HSMN NewsFeed - 23 Sep 2008
BSD Medical Corp. Announces ESMO Recommends Hyperthermia as 'Standard Therapy' for Soft Tissue Sarcoma
Devices Oncology
 HSMN NewsFeed - 23 Sep 2008
Neotropix Appoints Anthony Williams, M.D., as Its Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 Sep 2008
Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Aug 2008
Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Aug 2008
Craig W. Philips Takes Helm at CTI
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Jul 2008
BSD Medical's Premier Cancer Treatment System Can Now Treat Children's Cancers
Devices Oncology
 HSMN NewsFeed - 9 Jul 2008
FDA Grants Epeius Biotechnologies' Rexin-G a Third Orphan Drug Designation, This Time for the Treatment of Soft Tissue Sarcomas
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 May 2008
Nanomedicine Company Nanobiotix Elects Former Sanofi-Aventis Oncology Researcher Elsa Borghi, MD, as its Medical Director
Biopharmaceuticals Devices Oncology
 HSMN NewsFeed - 9 May 2008
ZIOPHARM Receives FDA Orphan Drug Designation for Palifosfamide (ZIO-201) in the Treatment of Soft Tissue Sarcoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Feb 2008
Infinity and MedImmune Announce Approval for Generic Name for Novel Hsp90 Inhibitor
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jan 2008
Delcath Appoints Three Leading Physicians to Its Newly Formed Scientific Advisory Board
Devices Drug Delivery Oncology Personnel
 HSMN NewsFeed - 17 Sep 2007
Infinity and MedImmune Receive Orphan Drug Designation for IPI-504 for Treatment of Gastroinstestinal Stromal Tumors
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Sep 2007
University of Dusseldorf Orders BSD-2000/3D/MR Cancer Treatment System
Devices Oncology
 HSMN NewsFeed - 25 Jul 2007
Cell Therapeutics, Inc. (CTI) Announces Agreement to Acquire SMi; Gains Global Rights to Brostallicin, in a New Class of Cancer Killing Agents
Biopharmaceuticals Mergers & Acquisitions Oncology
 HSMN NewsFeed - 4 Jun 2007
GSK's Pazopanib Shows Positive Results in Patients With Advanced Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Hyperthermia Plus Chemotherapy Nearly Doubles Disease-Free Survival Compared to Chemotherapy Alone for Sarcoma Cancer Patients
Devices Oncology
 HSMN NewsFeed - 1 May 2007
Results of 340 Patient Phase III Study Using BSD Medical's Cancer Therapy Systems to Be Announced at ASCO Annual Meeting
Devices Oncology
 HSMN NewsFeed - 12 Apr 2007
Positive Results Prompt US National Cancer Institute to Make Gleevec(R) Available To Patients in Post-Surgical GIST Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Apr 2007
Threshold Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating Glufosfamide in Patients With Soft Tissue Sarcoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Feb 2007
Threshold Pharmaceuticals Announces That a Phase 3 Clinical Trial of Glufosfamide for Treatment of Pancreatic Cancer Did Not Meet Its Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Dec 2006
BSD Medical Announces Completion of 340 Patient Cancer Study
Devices Oncology
 HSMN NewsFeed - 5 Oct 2006
Array BioPharma Appoints April H. Teitelbaum, MD, MS, FACP Vice President of Clinical Development - Oncology
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 May 2006
NCCN Announces Important Updates to Soft Tissue Sarcoma Guidelines
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 26

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 26 additional stories matching:
Soft Tissue Sarcoma
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.